She's remaking the abortion landscape one pill at a time

Telehealth Abortion Provider Operates Under State Shield Laws Amid Federal Court Challenges

Dr. Angel Foster directs operations for the Massachusetts Medication Abortion Access Project, known as The MAP, from a Boston-area office. The organization provides medication abortion services through telehealth. On a recent visit, Foster showed medical students bins of Priority Mail packages containing mifepristone and misoprostol prepared for shipment. The facility stores supplies of both medications used in the standard two-drug regimen.

The MAP began operations in 2023 after the Supreme Court decision in Dobbs v. Jackson Women’s Health Organization. Foster, who also holds a position at the University of Ottawa, has worked in reproductive health for three decades. The organization ships medication to patients in multiple states. According to data reviewed for this article, The MAP has served approximately 3,500 patients since late 2023. Broader estimates for shield-law providers indicate roughly 9,200 telehealth shipments per month nationwide.

Volunteers assemble packages twice weekly. Each package contains the medications, instruction sheets on ectopic pregnancy signs and privacy, and a printed card. Sessions process around 500 shipments. The organization has drawn volunteers through its public activities. Foster has described the group’s approach as avoiding advance compliance with potential restrictions.

In April, Louisiana filed a petition in the 5th U.S. Circuit Court of Appeals seeking to suspend FDA rules that permit telehealth prescribing and mailing of mifepristone. The complaint referenced a 2024 photograph of a packing session at The MAP. The filing described the activity as a scheme to distribute medication into states with restrictions. The MAP operates from Massachusetts, which maintains shield laws that protect providers who prescribe and mail medication to patients in states where abortion is restricted.

On May 1, the 5th Circuit issued an order suspending the telehealth rules for mifepristone. The decision created uncertainty for pending orders. The MAP shifted preparation toward misoprostol-only regimens for some shipments. Misoprostol is approved for other medical uses including ulcer treatment and labor induction. Medical literature documents its effectiveness as a single agent for pregnancy termination in certain protocols, though efficacy rates differ from the two-drug combination.

The Supreme Court later stayed the 5th Circuit order and returned the case to lower courts. Mail-order mifepristone remained available under existing FDA rules pending further proceedings. Justice Samuel Alito dissented from the stay. The MAP continued both two-drug and single-drug preparations while monitoring developments.

Foster has stated that the organization maintains stockpiles to continue shipments during potential supply interruptions. The MAP’s medical director, Dr. Maureen Paul, has referred to the network of providers as a parallel system for medication distribution. Patients contacting the service have expressed uncertainty about legitimacy in states with bans, according to Foster. The organization responds to such inquiries by confirming its operations.

The standard regimen uses mifepristone followed by misoprostol. Telehealth requests for medication abortion increased after Dobbs in states without restrictions. National data on total abortion numbers show variation depending on the source and time period examined. Some reports indicate overall clinician-supported procedures rose in certain metrics, while others note differences by state and method.

The MAP’s shipments reach patients in states with near-total bans and in states with gestational limits. Shield laws in several states, including Massachusetts, New York, and California, provide civil and criminal protections for out-of-state providers. These statutes allow continued mailing even when the patient’s state prohibits the procedure. The legal framework has enabled multiple organizations to maintain volume after 2022.

Foster has participated in discussions with other providers about contingency planning. In the event of further court orders limiting mifepristone access, the group has prepared misoprostol-only instructions and consent forms. Studies on misoprostol-only regimens exist in international settings, and The MAP has proposed collecting U.S. telehealth outcome data if the single-drug protocol is used at scale.

Volunteer packing events use standard Priority Mail cartons selected for discretion. Contents are checked for accuracy before sealing. The organization has received funding from individual donors, including a pledge reported after media coverage of its activities. Foster’s prior email signature included a graphic of reproductive anatomy; current communications focus on operational updates.

The Louisiana litigation remains in lower courts. Providers continue shipments under current federal rules while preparing alternative protocols. Patients in restricted states who receive medication report varying experiences with access and follow-up care. The MAP maintains a website with information on its process and eligibility criteria.

Operations rely on licensed clinicians for prescriptions. Packaging and mailing occur from the Massachusetts location. The organization has stated its intent to sustain services through existing legal protections and medication alternatives. Data collection on outcomes continues as part of routine quality monitoring.

Additional background on medication abortion shows that mifepristone received FDA approval in 2000 for use up to seven weeks, later expanded. Misoprostol was already available for other indications. Combination use became the most common method in the United States. Telehealth models emerged before Dobbs in states with fewer restrictions and expanded afterward through shield-law jurisdictions.

Foster has described the goal of maintaining access during periods of legal uncertainty. The MAP has adjusted workflows in response to the May court developments and subsequent stay. Staff and volunteers continue twice-weekly assembly sessions. Patient inquiries about service legitimacy are addressed directly in correspondence.

The current status leaves telehealth mifepristone available under FDA rules while litigation proceeds. Misoprostol remains obtainable through standard pharmaceutical channels. Providers in shield-law states continue operations within the boundaries of those statutes. The MAP has not released updated monthly shipment figures beyond the earlier total of approximately 3,500 patients served since its start.

This account draws on direct observation of operations, court filings, and statements from Foster and Yanow. It incorporates verified patient volume data and the explicit role of Massachusetts shield laws in enabling out-of-state shipments. Legal outcomes remain subject to further judicial review.